Agilent Technologies Inc


Want a discount? Become a member by purchasing Annual Subscription!
SKU: A Category:


Agilent has recently been in the news for expanding its product portfolio through the launch of the 8697 Headspace Sampler. The company’s new product launches are geared towards an increased focus on segments with high growth potential. Agilent has shown a visible strength in the cell analysis and mass spectrometry domain and with pharmaceutical companies gaining momentum, the stock could continue its growth trajectory. The company’s variety of diagnostic offerings helped deliver a strong 2020 and the company has started 2021 on a positive note with a good result, showing strength in food and pharma. Hence, we upgrade the stock to an ‘Outperform’ rating with a revised target price.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!